Large Cell Lymphoma Pilot Study III

• Status: Completed
• Trial end date: 2001-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to find out if it is feasible to deliver a multi-agent chemotherapy regimen which features a shorter, more intensive, immunophenotype-directed approach, and includes an intensification phase with hematopoietic stem cell support for children with large cell lymphoma

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: St. Jude Children's Research Hospital
• Treatments: Carboplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Ifosfamide; Methotrexate; Prednisone; Trimethoprim, Sulfamethoxazole Drug Combination; Vinblastine; Vincristine

Criteria

Inclusion Criteria:

• Patient must be previously untreated, except for steroids or emergency radiation therapy.

• Patient must be less than or equal to 18 years of age.

• Patient must have a histologic diagnosis of large cell Non-Hodgkin lymphoma.

• The immunophenotype of tumor cells must be either T-cell or non-B-cell, non-T-cell.

Exclusion Criteria:

• Participants with B-cell immunophenotype NHL.